HSGX vs. MLSS, APT, LGMK, AHPI, MREO, ANGO, BNTC, ZBIO, OFIX, and ATAI
Should you be buying Histogenics stock or one of its competitors? The main competitors of Histogenics include Milestone Scientific (MLSS), Alpha Pro Tech (APT), LogicMark (LGMK), Allied Healthcare Products (AHPI), Mereo BioPharma Group (MREO), AngioDynamics (ANGO), Benitec Biopharma (BNTC), Zenas BioPharma (ZBIO), Orthofix Medical (OFIX), and atai Life Sciences (ATAI).
Histogenics vs. Its Competitors
Milestone Scientific (NYSE:MLSS) and Histogenics (NASDAQ:HSGX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
Histogenics has a net margin of 0.00% compared to Milestone Scientific's net margin of -52.01%. Histogenics' return on equity of -34.96% beat Milestone Scientific's return on equity.
Milestone Scientific has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Histogenics has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500.
In the previous week, Milestone Scientific had 2 more articles in the media than Histogenics. MarketBeat recorded 2 mentions for Milestone Scientific and 0 mentions for Histogenics. Histogenics' average media sentiment score of 0.00 beat Milestone Scientific's score of -0.04 indicating that Histogenics is being referred to more favorably in the news media.
Milestone Scientific has higher revenue and earnings than Histogenics. Milestone Scientific is trading at a lower price-to-earnings ratio than Histogenics, indicating that it is currently the more affordable of the two stocks.
Milestone Scientific currently has a consensus price target of $1.25, indicating a potential upside of 58.21%. Given Milestone Scientific's stronger consensus rating and higher possible upside, equities analysts clearly believe Milestone Scientific is more favorable than Histogenics.
Histogenics received 357 more outperform votes than Milestone Scientific when rated by MarketBeat users. Likewise, 71.66% of users gave Histogenics an outperform vote while only 2.17% of users gave Milestone Scientific an outperform vote.
5.8% of Milestone Scientific shares are owned by institutional investors. Comparatively, 40.4% of Histogenics shares are owned by institutional investors. 24.8% of Milestone Scientific shares are owned by company insiders. Comparatively, 19.7% of Histogenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Histogenics beats Milestone Scientific on 9 of the 17 factors compared between the two stocks.
Get Histogenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HSGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Histogenics Competitors List
Related Companies and Tools
This page (NASDAQ:HSGX) was last updated on 6/25/2025 by MarketBeat.com Staff
